Antitumor effects of BMS-777607 on ovarian cancer cells with constitutively activated c-MET
Tài liệu tham khảo
Siegel, 2015, Cancer statistics, 2015, CA: Cancer J Clin, 65, 5
Bast, 2009, The biology of ovarian cancer: new opportunities for translation, Nat Rev Cancer, 9, 415, 10.1038/nrc2644
Kobayashi, 2012, Biomarkers for screening, diagnosis, and monitoring of ovarian cancer, Cancer Epidemiol Prev Biomark, 21, 1902, 10.1158/1055-9965.EPI-12-0646
Zhang, 2009, Targeting cancer with small molecule kinase inhibitors, Nat Rev Cancer, 9, 28, 10.1038/nrc2559
Siegel-Lakhai, 2005, Current knowledge and future directions of the selective epidermal growth factor receptor inhibitors erlotinib (Tarceva®) and gefitinib (Iressa®), Oncologist, 10, 579, 10.1634/theoncologist.10-8-579
Ryan, 2008, FDA drug approval summary: lapatinib in combination with capecitabine for previously treated metastatic breast cancer that overexpresses HER-2, Oncologist, 13, 1114, 10.1634/theoncologist.2008-0816
Birchmeier, 2003, Met, metastasis, motility and more, Nat Rev Mol Cell Biol, 4, 915, 10.1038/nrm1261
Sawada, 2007, c-Met overexpression is a prognostic factor in ovarian cancer and an effective target for inhibition of peritoneal dissemination and invasion, Cancer Res, 67, 1670, 10.1158/0008-5472.CAN-06-1147
Ma, 2007, Downstream signalling and specific inhibition of c-MET/HGF pathway in small cell lung cancer: implications for tumour invasion, Br J Cancer, 97, 368, 10.1038/sj.bjc.6603884
Comoglio, 2008, Drug development of MET inhibitors: targeting oncogene addiction and expedience, Nat Rev Drug Discov, 7, 504, 10.1038/nrd2530
Kwon, 2015, Effective inhibition of c-MET-mediated signaling, growth and migration of ovarian cancer cells is influenced by the ovarian tissue microenvironment, Oncogene, 34, 144, 10.1038/onc.2013.539
Organ, 2011, An overview of the c-MET signaling pathway, Ther Adv Med Oncol, 3, S7, 10.1177/1758834011422556
Lai, 2009, Crosstalk in Met receptor oncogenesis, Trends Cell Biol, 19, 542, 10.1016/j.tcb.2009.07.002
Schroeder, 2009, Discovery of N-(4-(2-amino-3-chloropyridin-4-yloxy)-3-fluorophenyl)-4-ethoxy-1-(4-fluorophenyl)-2-oxo-1, 2-dihydropyridine-3-carboxamide (BMS-777607), a selective and orally efficacious inhibitor of the Met kinase superfamily, J Med Chem, 52, 1251, 10.1021/jm801586s
Dai, 2010, BMS-777607, a small-molecule Met kinase inhibitor, suppresses hepatocyte growth factor–stimulated prostate cancer metastatic phenotype in vitro, Mol Cancer Therapeut, 9, 1554, 10.1158/1535-7163.MCT-10-0359
Sharma, 2013, Small-molecule inhibitor BMS-777607 induces breast cancer cell polyploidy with increased resistance to cytotoxic chemotherapy agents, Mol Cancer Therapeut, 12, 725, 10.1158/1535-7163.MCT-12-1079
Toss, 2015, Molecular characterization and targeted therapeutic approaches in breast cancer, Breast Cancer Res, 17, 60, 10.1186/s13058-015-0560-9
Sulpice, 2009, Cross-talk between the VEGF-A and HGF signalling pathways in endothelial cells, Biol Cell, 101, 525, 10.1042/BC20080221
Banerjee, 2013, New strategies in the treatment of ovarian cancer: current clinical perspectives and future potential, Clin Cancer Res, 19, 961, 10.1158/1078-0432.CCR-12-2243
Imai, 2006, Comparing antibody and small-molecule therapies for cancer, Nat Rev Cancer, 6, 714, 10.1038/nrc1913
Andrews, 2004, Aurora B regulates MCAK at the mitotic centromere, Dev Cell, 6, 253, 10.1016/S1534-5807(04)00025-5
Hirota, 2005, Histone H3 serine 10 phosphorylation by Aurora B causes HP1 dissociation from heterochromatin, Nature, 438, 1176, 10.1038/nature04254
Yan, 2015, The efficacy of synchronous combination of chemotherapy and EGFR TKIs for the first-line treatment of NSCLC: a systematic analysis, PloS One, 10, 10.1371/journal.pone.0135829
Zeng, 2014, Synergistic activities of MET/RON inhibitor BMS-777607 and mTOR inhibitor AZD8055 to polyploid cells derived from pancreatic cancer and cancer stem cells, Mol Cancer Therapeut, 13, 37, 10.1158/1535-7163.MCT-13-0242